Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
February 13, 2023 19:47 ET
|
Amarin Corporation plc
Glass Lewis Recognizes that Change Led by Amarin’s New Board is Already Underway, and Sarissa Representation is Not Warranted Report Notes that Sarissa’s Underqualified Slate of Nominees Include...
Amarin Shareholders Invited to Webcast with Board and Management Team
February 13, 2023 08:00 ET
|
Amarin Corporation plc
-- Board and Management Team to Answer Shareholder Questions -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the...
Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
February 09, 2023 08:00 ET
|
Amarin Corporation plc
Letter Underscores the Change That is Being Led by Amarin’s New Board Highlights Sarissa’s Track Record of Value Destruction in the Healthcare Space Sarissa Continues to Mislead Shareholders by...
Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
February 06, 2023 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a letter to shareholders...
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
February 02, 2023 16:30 ET
|
Amarin Corporation plc
Significantly Refreshed Board Overseeing Successful Execution of Amarin’s Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa’s Slate in Every Critical Area Chairman Per...
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
January 31, 2023 08:24 ET
|
Amarin Corporation plc
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly...
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
January 27, 2023 08:45 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent...
Amarin to Present at SVB Securities Global Biopharma Conference
January 27, 2023 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
January 19, 2023 07:00 ET
|
Amarin Corporation plc
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder...
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
January 11, 2023 16:33 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital...